RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma * Metastatic or recurrent disease * Not curable by standard therapies * Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease * Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies * Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression * Meets 1 of the following criteria: * At least 1 measurable site of disease ≥ 2 cm by radiography * Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator * RAAG12 expression confirmed\* by immunohistochemistry NOTE: \*Not required for patients with colon, pancreatic, or gastric adenocarcinoma * No evidence of residual or recurrent CNS metastases * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age * 18 and over Sex * Not specified Menopausal status * Not specified Performance status * ECOG 0-1 Life expectancy * More than 3 months Hematopoietic * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL (transfusions allowed) * Absolute neutrophil count ≥ 1,500/mm\^3 Hepatic * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * γ-glutamyl transferase ≤ 2.5 times ULN * Adequate hepatic function sufficient to undergo study therapy Renal * Creatinine \< 1.5 mg/dL * Adequate renal function sufficient to undergo study therapy Cardiovascular * No New York Heart Association class III or IV heart disease * No thrombosis within the past 3 months, including any of the following: * Deep vein thrombosis * Myocardial infarction * Stroke * Adequate cardiac function sufficient to undergo study therapy Pulmonary * No pulmonary embolism within the past 3 months * No significant pulmonary compromise, particularly dependence on supplemental oxygen on an as-needed or continuous basis * Adequate pulmonary function sufficient to undergo study therapy Immunologic * No active viral, bacterial or systemic fungal infection requiring parenteral therapy within the past 4 weeks * No history of chronic or recurrent infection requiring continual antiviral, antifungal, or antibacterial agents * No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in study drug Other * Amylase and lipase normal * No other primary malignancy within the past 3 years except for the following: * Treated non-melanoma skin cancer * Carcinoma in situ of the cervix by biopsy * Squamous intraepithelial lesion of the cervix by PAP smear * Localized prostate cancer (Gleason score \< 6) * Resected melanoma in situ * No other serious medical condition that would preclude study participation * No dementia or altered mental status that would preclude giving informed consent * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy * At least 3 half-lives since prior monoclonal antibody therapy * No concurrent vaccinations * No concurrent prophylactic hematologic growth factors Chemotherapy * At least 4 weeks since prior chemotherapy Endocrine therapy * No concurrent steroids except for the following: * Inhaled, ophthalmic, or nasal steroids * Stable dose of oral prednisone (or equivalent) ≤ 10 mg/day Radiotherapy * At least 4 weeks since prior radiotherapy Surgery * More than 4 weeks since prior major surgery Other * More than 4 weeks since prior investigational agents * Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy was completed within the past week * No other concurrent antineoplastic therapy * No concurrent immunosuppressive medications * No other concurrent investigational agents * No concurrent vitamins except those approved by the medical monitor * Concurrent daily multivitamin allowed * Concurrent bisphosphonates allowed provided patient is on stable dose for ≥ 1 month prior to study entry